Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Allogeneic (Allo-SCT) Versus Autologous Stem-Cell Transplantation (Auto-SCT) after Relapse to First Line Auto-SCT in Multiple Myeloma: A Meta-Analysis with Predominantly Individual Patient Data

Heinz Ludwig, Takashi Ikeda, Cesar O. Freytes, Koji Kawamura, Yoshiko Atsuta, Hiroyuki Takamatsu, David H. Vesole, Hari Parameswaran, Axel Hinke

Blood (2023) 142 (Supplement 1): 7100.

https://doi.org/10.1182/blood-2023-179105

Published: 2023

Journal Articles

Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Blood (2021) 137 (4): 556–568.

https://doi.org/10.1182/blood.2020006252

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

John E. Godwin, MD, Cesar O. Freytes, MD, Michael Maris, MD, Don A. Stevens, MD, Daanish Hoda, MD, Bassam Mattar, MD, Juan C. Varela, MDPhD, Mohamad Cherry, MDMS, James Essell, MD, Jay Courtright, MD, Suzanne R. Fanning, DO, Habte A. Yimer, MD, Nikolaus S. Trede, MD PhD, Marina Youssef, PharmD, James Lymp, PhD, Carlos Bachier, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-136640

Published: 2020

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children

Andrew C. Harris, MD, Jaap Jan Boelens, MDPhD, Kwang Woo Ahn, PhD, Mingwei Fei, MS, Allistair Abraham, MD, Andrew Artz, MD, Christopher C. Dvorak, MD, Haydar Frangoul, MD, Cesar O Freytes, MD, Robert Peter Gale, MD PhD, Sanghee Hong, MD, Hillard M. Lazarus, MD, Shin Mineishi, MD, Taiga Nishihori, MD, Tracey O'Brien, MD, Kirsten M. Williams, MD, Marcelo C. Pasquini, MD, John E Levine, MD MS

Blood (2016) 128 (22): 664.

https://doi.org/10.1182/blood.V128.22.664.664

Published: 2016

Journal Articles

Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM)

Natalie Scott Callander, MD, Cesar O. Freytes, MD, Suhong Luo, MPH, Kenneth R Carson, MD PhD

Blood (2015) 126 (23): 4194.

https://doi.org/10.1182/blood.V126.23.4194.4194

Published: 2015

Journal Articles

The Veterans Health Administration Provides Equal Access to Autologous Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

Cesar O. Freytes, MD, Natalie S Callander, MD, Stacey A Goodman, MD, Suhong Luo, MPH, Juan J. Toro, MD MSci, Kenneth R Carson, MD

Blood (2014) 124 (21): 2629.

https://doi.org/10.1182/blood.V124.21.2629.2629

Published: 2014

Journal Articles

Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial

Blood (2014) 124 (21): 209.

https://doi.org/10.1182/blood.V124.21.209.209

Published: 2014

Journal Articles

Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America

Blood (2013) 122 (21): 768.

https://doi.org/10.1182/blood.V122.21.768.768

Published: 2013

Journal Articles

Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr

William A. Wood, MD, MPH, Stephanie J. Lee, MD, MPH, Ruta Brazauskas, PhD, Zhiwei Wang, MS, Mahmoud D. Aljurf, MD, Karen K. Ballen, MD, David K. Buchbinder, MD, MSHS, Jason Dehn, MPH, CHTC, César O Freytes, MD, Hillard M. Lazarus, MD, Charles F. LeMaistre, MD, Paulette Mehta, MD, MPH, David Szwajcer, MD, FRCPC, Steven Joffe, MD, MPH, Navneet S. Majhail, MD, MS

Blood (2013) 122 (21): 554.

https://doi.org/10.1182/blood.V122.21.554.554

Published: 2013

Journal Articles

Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Blood (2012) 120 (21): 3080.

https://doi.org/10.1182/blood.V120.21.3080.3080

Published: 2012

Journal Articles

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Blood (2012) 120 (21): 813.

https://doi.org/10.1182/blood.V120.21.813.813

Published: 2012

Journal Articles

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Blood (2012) 120 (20): 4256–4262.

https://doi.org/10.1182/blood-2012-06-436725

Published: 2012

Includes: Supplemental data

Journal Articles

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Cesar O. Freytes, MD, Juan J. Toro, MD, MSci, Rosa F. Yeh, PharmD, Edward A. Stadtmauer, MD, Voravit Ratanatharathorn, MD, Gorgun Akpek, MD, MHS, Entezam Sahovic, MD, Guido J. Tricot, MD, PhD, Paul J. Shaughnessy, MD, Darrell J. White, MD, Tulio E. Rodriguez, MD, Scott R. Solomon, MD, Louie H. Yu, BS, Shiva Patil, PhD, Yiping Sun, PhD, Elizabeth Armstrong, MS, Agnes Elekes, MD, Kazunobu Kato, MD, PhD, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 4509.

https://doi.org/10.1182/blood.V118.21.4509.4509

Published: 2011

Journal Articles

Nicotine Use During Mobilization Is Associated with More Efficient Stem Cell Collection

David J Haile, MD, Kenneth Utz, Pharm.D., BCOP, Juan J. Toro, MD, MS, Brenda L. Frye, MPAS, DHSc, Bonita Neumon, MPAS, Lee Shuko, MS, Cesar O. Freytes, MD

Blood (2011) 118 (21): 1934.

https://doi.org/10.1182/blood.V118.21.1934.1934

Published: 2011

Journal Articles

Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)

Cesar O. Freytes, MD, David H. Vesole, MD, PhD, Xiaobo Zhong, MS, Jennifer Le-Rademacher, PhD, Angela Dispenzieri, MD, Sagar Lonial, MD, Gustavo Milone, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 824.

https://doi.org/10.1182/blood.V118.21.824.824

Published: 2011

Journal Articles

Comparison of Clostridium Difficile Associated Diarrhea Detection by Enzyme Linked Immunosorbent Assay (EIA) and Polymerase Chain Reaction (PCR) in Autologous Hematopoietic Stem Cell Transplant (AHSCT) Recipients

Kenneth Utz, Pharm.D., BCOP, Christopher Frei, PharmD, MS, BCPS, Bonita Neumon, MPAS, Brenda L. Frye, MPAS, DHSc, Deanna Schneider, David J Haile, MD, Cesar O. Freytes, MD

Blood (2011) 118 (21): 4739.

https://doi.org/10.1182/blood.V118.21.4739.4739

Published: 2011

Journal Articles

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis

Blood (2011) 118 (7): 1979–1988.

https://doi.org/10.1182/blood-2011-02-337329

Published: 2011

Journal Articles

Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ.

Prakash Varadarajan, MD, Juan Toro, Robert M. Craig, Deanna Schneider, Ju-Hsien Chao, David Haile, Cesar O. Freytes, MD

Blood (2010) 116 (21): 1314.

https://doi.org/10.1182/blood.V116.21.1314.1314

Published: 2010

Journal Articles

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL)

Cesar O Freytes, MD, Jeanette Carreras, MPH, Mei-Jie Zhang, PhD, Ginna G. Laport, MD, Koen Van Besien, MD, Hillard M. Lazarus, MD, Parameswaran Hari, MD, MS

Blood (2008) 112 (11): 459.

https://doi.org/10.1182/blood.V112.11.459.459

Published: 2008

NARROW

Allogeneic (Allo-SCT) Versus Autologous Stem-Cell Transplantation (Auto-SCT) after Relapse to First Line Auto-SCT in Multiple Myeloma: A Meta-Analysis with Predominantly Individual Patient Data

Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children

Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM)

The Veterans Health Administration Provides Equal Access to Autologous Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial

Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America

Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr

Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Nicotine Use During Mobilization Is Associated with More Efficient Stem Cell Collection

Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)

Comparison of Clostridium Difficile Associated Diarrhea Detection by Enzyme Linked Immunosorbent Assay (EIA) and Polymerase Chain Reaction (PCR) in Autologous Hematopoietic Stem Cell Transplant (AHSCT) Recipients

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis

Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ.

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only